For decades, escalating global obesity prevalence and evidence of its major contribution to the most common causes of death and ill health was, at best, confined to discussions of prevention, and, at worst, stigmatised and ignored in policy, practice, and the media. However, the landscape has evolved rapidly with the use of therapies based on GLP-1 receptor agonists to treat obesity. Landmark developments in 2025 include the WHO global guideline recommending two GLP-1 receptor agonists for obesity care,1 and the inclusion of GLP-1 receptor agonists in the WHO Essential Medicines List to treat people living with obesity and diabetes and either cardiovascular or kidney disease.
The Lancet Global Health published a clinical update in Infectious Disease on 25 Feb 2026.
The item focuses on Therapies based on GLP-1 receptor agonists: significance, challenges, and opportunities.
Review the original article for the full source wording and details.